Scott Greenberg

Scott is a seasoned biotech executive who brings a wealth of experience spanning multiple therapeutic areas. Across his more than twenty years in industry, Scott’s career has been marked by a commitment to advancing innovative therapies that have the opportunity to meaningfully improve the lives of patients. His diverse functional experiences enable him to navigate the complexities of the biotech landscape with a unique and comprehensive perspective. Scott was most recently Chief Operating Officer of Aro Biotherapeutics, a biotech company focused on the development of targeted siRNA therapies, where he led fundraising efforts, business development, corporate strategy, finance and new product planning.

Prior to his role at Aro, Scott served as Vice President, Head of Operations at Roivant Sciences, where he was responsible for executive direction of newly established clinical-stage companies. Earlier in his career, Scott spent more than a decade at Celgene Corporation in multiple roles spanning business development, R&D strategy, R&D project leadership, sales and marketing. He began his career in investment banking at Goldman Sachs & Co. Scott has a dual degree, with a BS in Economics and a BA in Biological Basis of Behavior with a minor in Mathematics, from the University of Pennsylvania as well as an MBA from Harvard Business School.

‍